NRX Pharmaceuticals Inc
NRXP2.690USD
+0.100+3.86%
Market hours （ET）Quotes delayed by 15 min
46.05MMarket Cap
LossP/E TTM
More Details of NRX Pharmaceuticals Inc Company
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Company Info
Ticker SymbolNRXP
Company nameNRX Pharmaceuticals Inc
IPO dateNov 20, 2017
CEODr. Jonathan C. Javitt, M.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 20
Address1201 Orange Street
CityWILMINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code19801
Phone14842546134
Websitehttps://www.nrxpharma.com/
Ticker SymbolNRXP
IPO dateNov 20, 2017
CEODr. Jonathan C. Javitt, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Matthew P. Duffy
Mr. Matthew P. Duffy
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 20
Updated: Sun, Jul 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Javitt (Jonathan C)
8.77%
Anson Funds Management LP.
6.82%
Glytech LLC
5.57%
The Vanguard Group, Inc.
2.25%
AdvisorShares Investments, LLC
1.66%
Other
74.93%
Shareholders
Shareholders
Proportion
Javitt (Jonathan C)
8.77%
Anson Funds Management LP.
6.82%
Glytech LLC
5.57%
The Vanguard Group, Inc.
2.25%
AdvisorShares Investments, LLC
1.66%
Other
74.93%
Shareholder Types
Shareholders
Proportion
Individual Investor
10.31%
Hedge Fund
6.99%
Corporation
5.57%
Investment Advisor/Hedge Fund
3.96%
Investment Advisor
2.29%
Research Firm
0.09%
Other
70.78%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
66
5.05M
29.22%
+1.46M
2025Q1
66
4.06M
26.08%
+505.82K
2024Q4
70
3.94M
22.32%
-356.61K
2024Q3
83
3.57M
28.23%
-628.46K
2024Q2
86
3.38M
32.03%
-634.67K
2024Q1
92
3.27M
34.30%
-835.14K
2023Q4
98
3.31M
81.28%
-805.62K
2023Q3
101
3.31M
42.19%
-663.76K
2023Q2
103
3.89M
52.92%
+527.79K
2023Q1
100
3.14M
46.14%
-970.16K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Javitt (Jonathan C)
1.52M
8.77%
-199.00
-0.01%
Apr 29, 2025
Anson Funds Management LP.
1.18M
6.82%
+993.40K
+535.06%
Mar 31, 2025
Glytech LLC
963.48K
5.57%
+963.48K
--
Apr 29, 2025
The Vanguard Group, Inc.
388.93K
2.25%
+148.61K
+61.84%
Mar 31, 2025
AdvisorShares Investments, LLC
286.80K
1.66%
-23.52K
-7.58%
Mar 31, 2025
Hurvitz (Chaim)
221.48K
1.28%
+1.00
+0.00%
Apr 29, 2025
Geode Capital Management, L.L.C.
134.66K
0.78%
+60.41K
+81.35%
Mar 31, 2025
Marshall Wace LLP
89.09K
0.52%
+89.09K
--
Mar 31, 2025
Flynn (Patrick John)
44.45K
0.26%
-14.58K
-24.70%
Apr 29, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Psychedelics ETF
7.9%
iShares Micro-Cap ETF
0.01%
AdvisorShares Psychedelics ETF
Proportion7.9%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Date
Type
Ratio
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
